IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i10p6069-d817086.html
   My bibliography  Save this article

Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study

Author

Listed:
  • Aurora Zanghì

    (UOC Neurology, Sant’Elia Hospital, 93100 Caltanissetta, Italy
    These authors contributed equally to this work.)

  • Emanuele D’Amico

    (Department of Medical and Surgical Sciences, University of Foggia, 72100 Foggia, Italy
    These authors contributed equally to this work.)

  • Francesco Patti

    (Department “G.F. Ingrassia”, MS Center, University of Catania, 95125 Catania, Italy)

  • Carlo Avolio

    (Department of Medical and Surgical Sciences, University of Foggia, 72100 Foggia, Italy
    Multiple Sclerosis Center, Department of Neurosciences, Policlinico Riuniti Hospital, 72100 Foggia, Italy)

Abstract

Background: No consensus exists on the possibility to stop disease modifying therapies (DMTs) in Secondary Progressive Multiple Sclerosis (SPMS). Methods: The primary outcome was the time to reach 24-weeks confirmed Expanded Disability Status Scale (EDSS) 7.0. We enrolled all patients with a confirmed diagnosis of non-active SPMS (here, absence of clinical or radiological activity for at least 24 months before the conversion) between 1 January 2010 and 31 December 2015, at MS centers of Catania and Foggia, Italy. Patients were divided into two groups, according to the shared decision to stop DMTs (group A) or to maintain/switch to licensed interferon beta 1b for SPMS (group B). A Cox model adjusted with an inverse probability weighted propensity score (IPTW-PS) was employed. Results: A cohort of 311 patients was enrolled, 165 were in group A and 146 were in group B. Patients in the two groups were similar for baseline characteristics. The IPTW-PS adjusted Cox model for the event time to 24-weeks confirmed EDSS 7.0 did not show differences between the two groups (ExpB 0.96, CI 0.739–1.271, p = 0.819). Conclusions: In a real-world setting, in patients with non-active SPMS, the maintaining or switching to the licensed interferon beta 1b did not reduce the risk of reaching confirmed EDSS 7.0.

Suggested Citation

  • Aurora Zanghì & Emanuele D’Amico & Francesco Patti & Carlo Avolio, 2022. "Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study," IJERPH, MDPI, vol. 19(10), pages 1-7, May.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:10:p:6069-:d:817086
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/10/6069/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/10/6069/
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:10:p:6069-:d:817086. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.